The present invention provides a biomatrix layer comprising, consisting essentially of or consisting of a sulfated oligosaccharide at a concentration in the range of 0.1 μM to 1,000 μM and a peptide-polyethylene glycol-conjugate according to formula (I): PEG-R1-(BX)n (I) wherein B is lysine or arginine, X is selected from alanine, glycine, serine, threonine, tyrosine, glutamic acid or aspartic acid and n is an integer selected from 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20; R.sub.1 may be absent or is a peptide comprising 5 to 30 amino acids; PEG is comprised at a concentration in the range of 0.1 μM to 1,000 μM; R1, if present, is comprised at a concentration in the range of 0.1 μM to 4,000 μM; (BX)n is comprised at a concentration in the range of 0.25 μM to 1,000 μM. The invention further relates to processes for assembling the biomatrix layer. The biomatrix layer can be used in various biomedical applications, such as neuroprostheses, biosensors, nerve grafts, cell culture and encapsulation of cells and microorganisms as well as for drug delivery.

Disclosed are therapeutic self-assembling molecules including a peptide sequence conjugated to one or more antiviral therapeutics to form a peptide-based antiviral prodrug capable of self-assembly into supramolecular structures with varying morphology in aqueous solutions, which can be injected subcutaneously or intramuscularly for the long-acting treatment of chronic viral infections.

Described herein are compositions and methods for a novel drug delivery platform using affinity homing. Also disclosed herein are a drug delivery system, methods for using the novel drug delivery platform and a kit.

Decreasing skin penetration lag times will improve the bioavailability of a topically administered roflumilast composition. A shorter skin penetration lag time provides quicker onset of disease relief and more consistent bioavailability as there is less transference to clothing or other people. The skin penetration lag time for roflumilast can be reduced by formulating a roflumilast composition to have a pH between 4.0-6.5 and/or combining roflumilast with an emulsifier blend comprising cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate.

Decreasing skin penetration lag times will improve the bioavailability of a topically administered roflumilast composition. A shorter skin penetration lag time provides quicker onset of disease relief and more consistent bioavailability as there is less transference to clothing or other people. The skin penetration lag time for roflumilast can be reduced by formulating a roflumilast composition to have a pH between 4.0-6.5 and/or combining roflumilast with an emulsifier blend comprising cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate.

The present disclosure provides a protein-release system for sustained release of proteins. The system includes a hydrogel comprising a polymeric network, proteins having a portion corresponding to a portion of a fragment crystallization (Fc) constant region of an antibody, and peptidic ligands covalently coupled to the polymeric network, the peptidic ligands comprising an amino acid sequence having a binding affinity to the portion of the Fc constant region, each protein being reversibly bound by affinity to the peptidic ligands.

Described are implantable devices comprising DNA nanostructures comprising a cell ligand at a proximal end tethered to an implantable substrate at a distal end for delivery of CpG oligodeoxynucleotides to cancer cells and methods of use and systems thereof.

Decreasing skin penetration lag times will improve the bioavailability of a topically administered roflumilast composition. A shorter skin penetration lag time provides quicker onset of disease relief and more consistent bioavailability as there is less transference to clothing or other people. The skin penetration lag time for roflumilast can be reduced by formulating a roflumilast composition to have a pH between 4.0 - 6.5 and/or combining roflumilast with an emulsifier blend comprising cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate.

Provided are nanoparticles for the selective death of cancer cells through ferroptosis and a method of preparing the same. More particularly, the nanoparticles are in a form in which a cancer cell-targeting hydrogel and iron particles are bound and aggregated, and are selectively accumulated in cancer cells, and thus exhibit an effective cancer cell killing effect through ferroptosis, and accordingly, are expected to exhibit high therapeutic effects due to less side effects.

The oral cavity is an ideal-site for small molecule, pharmaceutical delivery to the systemic circulation due to the highly-vascularized, oral mucosa, near-neutral pH conditions, and avoidance of gastric degradation and first-pass hepatic metabolism. Accordingly, a novel, saccharide-based, food-form, portable, individually wrapped, oral delivery systems that attaches to the oral mucosa for a longer contact-duration than current orally available formulas resulting in greater, small molecule bioavailability, and a more rapid, therapeutic effect are preferred and described.